New Risk • 20h
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: AU$209k (US$148k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$209k revenue, or US$148k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$9.4m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Reported Earnings • Aug 04
Full year 2026 earnings: EPS and revenues miss analyst expectations Full year 2026 results: AU$0.25 loss per share (improved from AU$0.73 loss in FY 2025). Net loss: AU$16.2m (loss narrowed 51% from FY 2025). Revenue missed analyst estimates by 90%. Earnings per share (EPS) also missed analyst estimates by 6.6%. Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Global Life Sciences industry. New Risk • Aug 04
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$15m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (AU$2.3m revenue, or US$1.6m). Announcement • Aug 03
Vitrafy Life Sciences Limited to Report Fiscal Year 2026 Results on Aug 04, 2026 Vitrafy Life Sciences Limited announced that they will report fiscal year 2026 results Pre-Market on Aug 04, 2026 New Risk • Jul 02
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 16% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 16% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$20m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (AU$2.3m revenue, or US$1.6m). New Risk • Jun 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$15m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (AU$2.3m revenue, or US$1.6m). New Risk • Jun 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$13m net loss in 2 years). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (AU$2.3m revenue, or US$1.6m). Announcement • Apr 23
Vitrafy Life Sciences Limited to Report Q3, 2026 Results on Apr 28, 2026 Vitrafy Life Sciences Limited announced that they will report Q3, 2026 results at 10:00 AM, AUS Eastern Standard Time on Apr 28, 2026 Major Estimate Revision • Feb 17
Consensus revenue estimates fall by 35% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from AU$2.81m to AU$1.83m. Forecast losses increased from -AU$0.221 to -AU$0.239 per share. Life Sciences industry in Australia expected to see average net income growth of 21% next year. Consensus price target up from AU$2.19 to AU$2.37. Share price fell 6.3% to AU$1.65 over the past week. New Risk • Feb 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 8.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 8.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$18m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$2.3m revenue, or US$1.7m). Market cap is less than US$100m (AU$109.2m market cap, or US$77.2m). Major Estimate Revision • Feb 10
Consensus revenue estimates fall by 26% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from AU$3.86m to AU$2.85m. Forecast losses increased from -AU$0.217 to -AU$0.224 per share. Life Sciences industry in Australia expected to see average net income growth of 24% next year. Consensus price target up from AU$2.06 to AU$2.22. Share price rose 6.7% to AU$1.76 over the past week. Reported Earnings • Feb 05
First half 2026 earnings released: AU$0.11 loss per share (vs AU$0.99 loss in 1H 2025) First half 2026 results: AU$0.11 loss per share (improved from AU$0.99 loss in 1H 2025). Net loss: AU$7.12m (loss narrowed 72% from 1H 2025). Revenue is forecast to grow 98% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Global Life Sciences industry. New Risk • Feb 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$7.8m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$2.3m revenue, or US$1.6m). Market cap is less than US$100m (AU$103.4m market cap, or US$72.6m). Announcement • Jan 29
Vitrafy Life Sciences Limited to Report First Half, 2026 Results on Feb 04, 2026 Vitrafy Life Sciences Limited announced that they will report first half, 2026 results on Feb 04, 2026 New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$1.0m revenue, or US$713k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.7m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$121.3m market cap, or US$82.5m). Board Change • Jan 07
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Vaughan Webber was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 04
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Vaughan Webber was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 20
Vitrafy Life Sciences Limited to Report Q1, 2026 Results on Oct 22, 2025 Vitrafy Life Sciences Limited announced that they will report Q1, 2026 results on Oct 22, 2025 Announcement • Oct 16
Vitrafy Life Sciences Limited, Annual General Meeting, Nov 20, 2025 Vitrafy Life Sciences Limited, Annual General Meeting, Nov 20, 2025. Location: level 5, 111 cecil street, south melbourne vic 3205, Australia New Risk • Aug 12
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$33m Forecast net loss in 3 years: AU$1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$1.0m revenue, or US$683k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.7m net loss in 3 years). Market cap is less than US$100m (AU$102.2m market cap, or US$66.6m). Breakeven Date Change • Aug 12
No longer forecast to breakeven The 2 analysts covering Vitrafy Life Sciences no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$1.35m in 2028. New consensus forecast suggests the company will make a loss of AU$136.9k in 2028. Reported Earnings • Aug 05
Full year 2025 earnings: Revenues miss analyst expectations Full year 2025 results: Net loss: AU$32.7m (loss widened 214% from FY 2024). Revenue missed analyst estimates by 38%. Revenue is forecast to grow 72% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry. Buy Or Sell Opportunity • Jul 21
Now 20% undervalued Over the last 90 days, the stock has risen 2.1% to AU$1.49. The fair value is estimated to be AU$1.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 141% over the last year. Earnings per share has grown by 18%. Buy Or Sell Opportunity • Jul 03
Now 24% undervalued Over the last 90 days, the stock has risen 12% to AU$1.41. The fair value is estimated to be AU$1.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 141% over the last year. Earnings per share has grown by 18%. Breakeven Date Change • Jun 30
Forecast to breakeven in 2028 The 2 analysts covering Vitrafy Life Sciences expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$1.40m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Buy Or Sell Opportunity • Apr 30
Now 27% overvalued after recent price rise Over the last 90 days, the stock has risen 3.7% to AU$1.70. The fair value is estimated to be AU$1.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 141% over the last year. Earnings per share has grown by 18%. Announcement • Apr 16
Vitrafy Life Sciences Limited to Report Q3, 2025 Results on Apr 29, 2025 Vitrafy Life Sciences Limited announced that they will report Q3, 2025 results on Apr 29, 2025 New Risk • Feb 18
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$36m Forecast net loss in 3 years: AU$4.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$4.1m net loss in 3 years). Market cap is less than US$100m (AU$91.9m market cap, or US$58.5m). Major Estimate Revision • Feb 12
Consensus EPS estimates fall by 113% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -AU$0.169 to -AU$0.361 per share. Revenue forecast unchanged at AU$2.68m. Life Sciences industry in Australia expected to see average net income growth of 27% next year. Consensus price target down from AU$2.39 to AU$2.32. Share price fell 11% to AU$1.45 over the past week. New Risk • Feb 10
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$10m Forecast net loss in 3 years: AU$4.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.8m free cash flow). Negative equity (-AU$25m). Revenue is less than US$1m (AU$37k revenue, or US$23k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$4.7m net loss in 3 years). Market cap is less than US$100m (AU$93.9m market cap, or US$58.9m). Breakeven Date Change • Feb 10
Forecast to breakeven in 2027 The 2 analysts covering Vitrafy Life Sciences expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 40% per year to 2026. The company is expected to make a profit of AU$797.4k in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule. Announcement • Feb 04
Vitrafy Life Sciences Limited to Report First Half, 2025 Results on Feb 06, 2025 Vitrafy Life Sciences Limited announced that they will report first half, 2025 results on Feb 06, 2025 Breakeven Date Change • Jan 23
No longer forecast to breakeven The 2 analysts covering Vitrafy Life Sciences no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$803.8k in 2027. New consensus forecast suggests the company will make a loss of AU$3.71m in 2027. New Risk • Jan 07
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$10m Forecast net loss in 3 years: AU$3.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.8m free cash flow). Shares are highly illiquid. Negative equity (-AU$25m). Revenue is less than US$1m (AU$37k revenue, or US$23k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$3.7m net loss in 3 years). Market cap is less than US$100m (AU$105.4m market cap, or US$65.8m). Recent Insider Transactions • Dec 11
Board Member recently bought AU$50k worth of stock On the 10th of December, John McBain bought around 28k shares on-market at roughly AU$1.82 per share. This transaction amounted to 1.5% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. New Risk • Nov 27
New major risk - Revenue and earnings growth Revenue has declined by 98% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.8m free cash flow). Shares are highly illiquid. Negative equity (-AU$25m). Revenue has declined by 98% over the past year. Revenue is less than US$1m (AU$37k revenue, or US$24k). Minor Risk Market cap is less than US$100m (AU$129.6m market cap, or US$84.0m). Reported Earnings • Nov 26
Full year 2024 earnings released Full year 2024 results: AU$0.16 loss per share. Net loss: AU$10.4m (loss widened 33% from FY 2023). 
